

1 Medication-related adverse events in patients with cancer and discrepancies in cystatin 2 C- versus creatinine-based eGFR

3
4 Paul E. Hanna, MD MSc^{1*}, Qiyu Wang, MD^{1*}, Ian Strohbehm, BA¹, Daiana Moreno, BS¹, Destiny
5 Harden, BA¹, Tianqi Ouyang, MPH¹, Nurit Katz-Agranov, MD¹, Harish Seethapathy MBBS¹,
6 Kerry L. Reynolds MD², Shruti Gupta, MD MPH³⁻⁴, David E. Leaf MD MMSc³, Meghan E. Sise,
7 MD MS¹

- 8
9 1. Division of Nephrology, Department of Medicine, Massachusetts General Hospital,
10 Boston, MA
11 2. Division of Hematology and Oncology, Department of Medicine, Massachusetts
12 General Hospital, Boston, MA
13 3. Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA
14 4. Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, MA

15
16 *Equal contribution

17
18 Corresponding Author:
19 Meghan Sise, MD, MS
20 165 Cambridge St. Suite 302
21 Boston, MA 02108
22 msise@partners.org
23 617-726-5050
24

25 Abstract

26 **Background:** Creatinine-based estimated glomerular filtration rate (eGFR_{CRE}) may overestimate
27 kidney function in patients with cancer. Cystatin C-based eGFR (eGFR_{CYS}) is an alternative
28 marker of kidney function. We investigated whether patients with an eGFR discrepancy, defined
29 as eGFR_{CYS} >30% lower than the concurrent eGFR_{CRE}, had an increased risk of adverse events
30 resulting from renally-cleared medications.

31 **Patients and Methods:** We conducted a cohort study of adult patients with cancer who had
32 serum creatinine and cystatin C measured on the same day between May 2010 and January
33 2022 at two academic cancer centers in Boston, MA. The primary outcome was the incidence of
34 each of the following medication-related adverse events: 1) supratherapeutic vancomycin levels
35 (>30µg/mL); 2) trimethoprim-sulfamethoxazole-related hyperkalemia (>5.5mEq/L); 3) baclofen-
36 induced neurotoxicity; and 4) supratherapeutic digoxin levels (>2.0ng/mL).

37 **Results:** 1988 patients with cancer had simultaneous eGFR_{CYS} and eGFR_{CRE}. The mean age
38 was 66 years (SD±14), 965 (49%) were female, and 1555 (78%) were non-Hispanic white.

39 eGFR discrepancy occurred in 579 patients (29%). Patients with eGFR discrepancy were more
40 likely to experience medication-related adverse events compared to those without eGFR
41 discrepancy: vancomycin levels $>30\mu\text{g/mL}$ (24% vs. 10%, $p=0.004$), trimethoprim-
42 sulfamethoxazole-related hyperkalemia (24% vs. 12%, $p=0.013$), baclofen-induced neurotoxicity
43 (25% vs. 0%, $p=0.13$), and supratherapeutic digoxin levels (38% vs. 0%, $p=0.03$). The adjusted
44 OR for vancomycin levels $>30\mu\text{g/mL}$ was 2.30 (95% CI 1.05 – 5.51, $p = 0.047$).

45 **Conclusion:** Among patients with cancer with simultaneous assessment of eGFR_{CYS} and
46 eGFR_{CRE}, medication-related adverse events occur more commonly in those with eGFR
47 discrepancy. These findings underscore the importance of accurate assessment of kidney
48 function and appropriate dosing of renally-cleared medications in patients with cancer.

49

50 Conflicts of interest:

51 S. Gupta reports research support from BTG International and GE Healthcare. She is a
52 member of GlaxoSmithKline's Global Anemia Council, a consultant for Secretome, and
53 president and founder of the American Society of Onconephrology. MES: Reports
54 research funding from Gilead, Merck, EMD Serono, and Angion. She has served as a
55 scientific advisory board member to Mallinckrodt, Travere, and Novartis. DEL reports
56 research support from BioPorto, BTG International, and Metro International Biotech
57 LLC. All remaining authors have no conflict of interest.

58

59 Disclaimers:

60 The results presented in this report have been presented at the American Society of
61 Onconephrology Symposium in a poster format, however they have not been published
62 previously in whole or part.

63

64 Running title: eGFR discrepancies in patients with cancer

65

66 Funding:

67 MES is funded by NIH grant R01DK130839

68 SG is funded by NIH grant K23DK125672

69 DEL is funded by NIH grants R01HL144566, R01DK125786, and R01DK126685

70

71 **Introduction:**

72
73 Accurate assessment of estimated glomerular filtration rate (eGFR) is key to dosing
74 renally-cleared medications. While the gold standard method for evaluating kidney function is
75 direct measurement of glomerular filtration rate (mGFR) using inulin or chromium-51 labeled
76 ethylenediamine tetra-acetic acid,¹ GFR estimation using serum creatinine is the most
77 commonly used method in both clinical practice and research.²⁻⁴ Creatinine is a byproduct of
78 muscle metabolism that is filtered and secreted by the kidneys. Despite continued
79 improvements of currently available eGFR equations, creatinine-based eGFR remains
80 imprecise and can overestimate kidney function, particularly in patients with sarcopenia.^{5, 6} This
81 can lead to inaccurate dosing of medications that require adjustment based on eGFR, such as
82 commonly used antibiotics, muscle relaxants, anti-epileptic drugs, blood thinners, and
83 antiarrhythmic medications.

84 Cystatin C is a low molecular weight (13K Dalton) protein produced by all nucleated
85 cells. It is freely filtered by the glomerulus and does not undergo reabsorption or secretion.⁷
86 Unlike creatinine, cystatin C is not readily affected by age, sex, muscle mass, or diet, and has
87 been increasingly used as an alternative to creatinine to estimate GFR.^{2, 5, 8} A recent, large
88 study in patients with solid tumors demonstrated that using an equation that combines both
89 creatinine and cystatin C is the most accurate way to estimate GFR.^{8, 9}

90 Because cancer is a significant risk factor for sarcopenia,¹⁰ we hypothesized that having
91 a cystatin C-based eGFR (eGFR_{CYS}) that is significantly lower than creatinine-based eGFR
92 (eGFR_{CRE}) would be common in patients with cancer. Given that patients with cancer are
93 commonly exposed to numerous medications that require dose adjustment by kidney function,
94 we hypothesized that adverse events related to renally-cleared medications would be higher in
95 patients with a large discrepancy between eGFR_{CYS} versus eGFR_{CRE}.

96

97 **Methods:**

98 *Patient population*

99 Using Mass General Brigham's centralized data warehouse, the Research Patient Data
100 Registry (RPDR)^{11, 12}, we identified adult patients with a pre-existing diagnosis of malignancy
101 who had both serum creatinine and cystatin C measurements on the same day between May
102 2010 and January 2022. eGFR_{CRE} was calculated using the CKD Epidemiology Collaboration
103 (CKD-EPI) 2021 race-free equation,⁵ while eGFR_{CYS} was calculated using the CKD
104 Epidemiology Collaboration (CKD-EPI) 2012 race-free equation.^{13, 14}

105

106 *Data collection*

107 The date of the first simultaneous eGFR_{CRE} and eGFR_{CYS} measurement was considered
108 the baseline date. Comorbidities were defined based on diagnosis codes appearing any time
109 prior to the baseline date, and concurrent medication use was defined by active prescription
110 within 1 year prior to the baseline date. Cancer type was determined by the most frequently
111 used cancer-related diagnosis code prior to the baseline. Baseline chronic kidney disease was
112 defined by the 2021 race free CKD-EPI equation that incorporates both serum creatinine and
113 cystatin C⁸, and chronic kidney disease was staged per Kidney Disease Improving Global
114 Outcomes (KDIGO) guidelines.¹⁵ Clinical diagnoses of medication adverse events were
115 determined by manual chart review by two investigators; with a third available to resolve
116 disagreement.

117

118 *Primary exposure*

119 The primary exposure was eGFR discrepancy, defined as eGFR_{CYS} more than 30%
120 lower than the eGFR_{CRE}; the reference group consisted of all other patients and included
121 patients whose eGFR_{CYS} was more than 30% greater than eGFR_{CRE} as this would not place
122 patients at risk factor for adverse medication side effects from renally-cleared medications. The

123 30% cut-off was chosen because it is commonly used in clinical studies to define the accuracy
124 of eGFR from measured GFR.^{9, 16} We additionally identified a subset of patients with severe
125 eGFR discrepancy, defined as eGFR_{CYS} more than 50% lower than eGFR_{CRE} and eGFR_{CYS} less
126 than 30 mL/min/1.73m².

127

128 *Primary outcome: Adverse events related to renally-cleared medications*

129 We examined the risk of selected medication adverse events using detailed chart
130 review. We selected medications (intravenous vancomycin, trimethoprim-sulfamethoxazole,
131 baclofen, and digoxin) that are typically dose-adjusted based on eGFR and whose side effects
132 could be quantified by drug level monitoring, laboratory abnormalities, or identified by chart
133 review. In all cases, we evaluated drug exposures that occurred within 90 days of the baseline
134 date.

135 The therapeutic range for a vancomycin trough level is 15-20µg/mL and levels greater
136 than 20µg/mL are considered supratherapeutic^{17, 18}. We defined severely elevated vancomycin
137 trough levels as those greater than >30 µg/mL and used manual chart review to exclude peak
138 values.¹⁹⁻²¹

139 Trimethoprim-sulfamethoxazole-related hyperkalemia was defined as a serum
140 potassium level >5.5mEq/L (Common Terminology Criteria for Adverse events [CTCAE v 4.0]
141 grade 2), and severe hyperkalemia was defined as a level >6.0mEq/L (grade 3) within 30 days
142 of starting trimethoprim-sulfamethoxazole. As a sensitivity analysis, we determined the average
143 rise in potassium after initiation of trimethoprim-sulfamethoxazole and the rate of an absolute
144 increase in serum potassium ≥0.5mEq/L from baseline.

145 Baclofen toxicity was determined by chart review. Baclofen toxicity was defined as
146 altered mental status, myoclonus, seizure, or orthostatic hypotension/dizziness warranting

147 discontinuation of the medication.^{22, 23} An investigator blinded to cystatin C values evaluated all
148 clinical documentation within 90 days of baseline to identify potential cases of baclofen toxicity.

149 Digoxin toxicity was determined by chart review. An investigator blinded to cystatin C
150 values evaluated all clinical documentation and digoxin levels obtained within 90 days of
151 baseline. Digoxin toxicity was defined as altered mental status, nausea, orthostatic hypotension,
152 or bradycardia attributed to digoxin by the treating team, with a corresponding digoxin trough
153 level above the therapeutic range.^{24, 25}

154

155 *Secondary outcomes*

156 We evaluated eGFR discrepancy and severe eGFR discrepancy as dependent variables
157 and determined which baseline characteristics and laboratory studies were associated with
158 eGFR discrepancy.

159 We evaluated the effect of eGFR discrepancy on 30-day mortality. Date of simultaneous
160 eGFR_{CRE} and eGFR_{CYS} served as day 0. Patients lost to follow-up within 30 days were censored
161 at their last visit.

162

163 *Statistical Analysis*

164 We reported baseline characteristics using counts and percentages for categorical
165 variables and means and standard deviations (SD) for normally distributed continuous variables,
166 and median and interquartile range for skewed variables. Logistic regression models were used
167 to examine the association between baseline demographics, comorbidities, medications,
168 laboratory studies, and eGFR discrepancy in a univariable model. Serum albumin and
169 hemoglobin were evaluated in clinically relevant categories shown in **Table 1**. Variables were
170 then selected based on clinical plausibility and information criteria (Akaike and Bayesian) to
171 generate the final multivariable model. The Wald Chi-squared test was used to assess the
172 significance of explanatory variables. The final model was adjusted for age, sex, race, eGFR_{CRE}.

173 cys, BMI, smoking, hypertension, coronary artery disease, diabetes, cirrhosis, malnutrition,
174 thyroid disease, proton pump inhibitor use, diuretic use, angiotensin converting enzyme inhibitor
175 or angiotensin receptor blocker use, corticosteroid use, serum albumin, and hemoglobin,
176 Chi-squared or Fisher's exact tests were used to assess differences in the rate of
177 medication adverse events across groups, as appropriate. As a sensitivity analysis, we
178 performed univariable and multivariable logistic regression to predict the odds of elevated
179 vancomycin level >30 µg/mL; the final multivariable model was adjusted for age, sex, race,
180 baseline eGFR_{CRE-CYS}, BMI, diabetes, and corticosteroid use. All comparisons were two-sided,
181 with p<0.05 considered significant. Kaplan-Meier survival curves and multivariable Cox
182 regression models were used to compare 30-day survival across groups. The final multivariable
183 model was adjusted for age, sex, race, baseline eGFR_{CRE-CYS}, BMI, coronary artery disease,
184 diabetes, cirrhosis, angiotensin converting enzyme inhibitor or angiotensin receptor blocker use,
185 proton pump inhibitor use, diuretic use, corticosteroid use, serum albumin, and hemoglobin
186 level. All analyses were performed using R 4.1.1 (R Foundation), SAS 9.4 (SAS Institute), and
187 GraphPad PRISM V.9.1.0 (GraphPad Software).

188

189 Informed Consent:

190 The Massachusetts General Brigham Institutional Review Board approved this retrospective
191 study and waived the need for informed consent.

192 **Results:**

193 *Baseline characteristics*

194 There were 1988 patients with cancer who had a simultaneous creatinine and cystatin C
195 measured between May 4th, 2010, and January 26th, 2022 (**Figure 1**). Mean age was 66 (SD 14
196 years), 965 (49%) were female, and 1555 (78%) were non-Hispanic white. Patients with a wide
197 array of cancer types were included (**Supplemental Table 1**).

198 A total of 579 patients (29%) had an eGFR_{CYS} more than 30% lower than eGFR_{CRE}. A
199 scatterplot of eGFR_{CRE} vs. eGFR_{CYS} is shown in **Supplemental Figure 1A** and the distribution
200 of the differences between eGFR_{CRE} and eGFR_{CYS} is shown in **Supplemental Figure 1B**. As
201 noted in the methods, the reference group included patients whose eGFR_{CYS} was within 30% of
202 the eGFR_{CRE}, as well as the 209 patients (10.5%) whose eGFR_{CYS} was 30% higher than
203 eGFR_{CRE}. Predictors of eGFR discrepancy in the multivariable logistic model included white race
204 (adjusted odds ratio [aOR] 1.54, 95% confidence interval [CI] 1.16–2.045, obesity with body-
205 mass-index (BMI) ≥ 30 vs. normal BMI 18.5-24.9 kg/m² (aOR 1.51, 95% CI 1.07–2.13), cirrhosis
206 (aOR 1.82, 95% CI 1.14–2.95), diuretic use (aOR 1.68, 95% CI 1.23–2.30), recent corticosteroid
207 use (aOR 1.70, 95% CI 1.28–2.24), hypoalbuminemia (aOR 5.48, 95% CI 3.84–7.86 for serum
208 albumin < 3.0 vs. ≥ 4.0 g/dL), and anemia (aOR 2.17, 95% CI 1.55–3.03 for hemoglobin < 10.0
209 vs. ≥ 12.0 g/dL) (**Figure 2, Supplemental Table 2**).

210 Hypoalbuminemia and anemia were the baseline factors most strongly associated with
211 having an eGFR discrepancy; there was a stepwise increase in the likelihood of eGFR
212 discrepancy as albumin and hemoglobin levels decreased (**Figure 3, Supplemental Figure 2**).
213 Among patients with albumin ≥ 4.0 g/dL only 174/1224 (14%) had an eGFR discrepancy,
214 compared to 198/297 (67%) in patients with albumin < 3.0 g/dL. Among patients with
215 hemoglobin ≥ 12 g/dL only 117/886 (13%) had an eGFR discrepancy, compared to 130/196
216 (66%) in patients with hemoglobin < 8.0 g/dL.

217 There were 139 patients (7.0% of the overall cohort) who had severe eGFR discrepancy
218 (eGFR_{CYS} > 50% lower than eGFR_{CRE} and eGFR_{CYS} < 30mL/min/1.73m²) (**Supplemental Table**
219 **3**). Predictors of severe eGFR discrepancy were similar to eGFR discrepancy and are shown in
220 **Supplemental Table 4**. The rate of eGFR discrepancy and severe eGFR discrepancy varied by
221 cancer type (**Supplemental Figure 3**).

222

223 *Medication-related Adverse Events*

224 *Vancomycin*

225 There were 447 patients who received vancomycin within 90 days of the baseline date,
226 of whom 286 (64%) had a vancomycin trough measured (**Figure 1**). Patients with eGFR
227 discrepancy were more likely to have significantly elevated vancomycin trough levels than the
228 reference group: 129 of 193 (67%) vs. 37 of 93 (40%) of the reference group had a vancomycin
229 level above the therapeutic range ($P < 0.001$); 46 of 193 (24%) vs. 9 of 93 (10%) had trough
230 level >30 µcg/mL ($P = 0.004$); 15 of 193 (8%) vs. 0 of 93 (0%) had a trough level >40 µcg/mL (P
231 = 0.003) (**Figure 4A**). The rate of elevated vancomycin trough levels was even higher in
232 patients with severe eGFR discrepancy (**Figure 4A**). After adjustment for baseline
233 demographics, comorbidities, and baseline laboratory studies, patients with eGFR discrepancy
234 had a 2.30-fold adjusted OR (95% CI 1.05 – 5.51) of having a significantly elevated vancomycin
235 trough level >30 µg/mL (**Supplemental Table 5**).

236

237 *Trimethoprim-sulfamethoxazole*

238 There were 280 patients who received trimethoprim-sulfamethoxazole within 90 days of
239 the baseline date. We excluded 30 (11%) who did not have a serum potassium level checked
240 within 30 days of starting trimethoprim-sulfamethoxazole (**Figure 1**). Patients with eGFR
241 discrepancy were more likely to experience hyperkalemia (potassium >5.5mEq/L) after starting

242 trimethoprim-sulfamethoxazole compared to the reference group 33 of 135 (24%) vs. 14 of 115
243 (12%), $P = 0.013$ (**Figure 4B**). The rate of trimethoprim-sulfamethoxazole-related hyperkalemia
244 was even greater in patients with severe eGFR discrepancy, affecting 15 of 45 (33%) of patients
245 ($P = 0.0018$) (**Figure 4B**). A similar trend was found when evaluating the rate of grade 3
246 hyperkalemia (defined by a potassium level $> 6.0\text{mEq}$) (**Figure 4B**).

247

248 *Baclofen*

249 There were 32 patients newly prescribed baclofen within 90 days of baseline (**Figure 1**).
250 Five of the 20 patients (25%) with eGFR discrepancy developed clinical evidence of baclofen
251 toxicity which prompted discontinuation of the medication compared to none of the 12 patients
252 in the reference group ($P = 0.13$) (**Figure 5A**). Among those with severe eGFR discrepancy, 3
253 out of 8 (37.5%) developed baclofen toxicity. The most common symptom of baclofen toxicity
254 was somnolence/depressed level of consciousness (3 cases). Two additional patients
255 developed severe orthostatic hypotension.

256

257 *Digoxin*

258 There were 102 patients who were prescribed digoxin (**Figure 1**), of whom 34 (33%) had
259 at least one digoxin level measured. Out of the 24 patients with eGFR discrepancy, 9 patients
260 (38%) had a digoxin trough level above the therapeutic range ($>2.0\text{ ng/mL}$) compared to none of
261 the 10 patients in the reference group ($P = 0.034$). Two patients (8.3%) were diagnosed with
262 clinical digoxin toxicity, including one who required digoxin immune fab (**Supplemental Table**
263 **6**); both patients diagnosed with clinical digoxin toxicity met criteria for severe eGFR
264 discrepancy (**Figure 5B**).

265

266 Thirty-day survival

267 132 patients (7%) died within 30 days and 173 (9%) were lost to follow-up prior to 30
268 days. There was significantly higher 30-day mortality in patients with eGFR discrepancy
269 compared to the reference group (**Figure 6**). Even after adjustment for age, sex, race, baseline
270 comorbidities, laboratory tests, and medication use, patients with eGFR discrepancy had a 1.97-
271 fold increased hazard of death (95% CI 1.29–3.01), compared to the reference group (**Figure 6,**
272 **Supplemental Table 7**).

273

274

275 **Discussion:**

276 Our study showed that in a cohort of patients with a history of cancer who have
277 concurrent creatinine and cystatin C measurement, almost 1 out of 3 had an $eGFR_{CYS}$ more
278 than 30% lower than $eGFR_{CRE}$. The high rate of eGFR discrepancy in patients with cancer
279 poses a challenge for clinical decision making and signifies an important knowledge gap in
280 appropriate dose adjustment of medications that primarily undergo renal clearance. We found a
281 considerably higher rate of adverse events associated with select renally-cleared medications in
282 patients with eGFR discrepancy compared to our reference group.

283 Accurate dosing of renally-cleared medications is a challenge in patients with cancer,
284 among whom sarcopenia is common and overestimation of GFR by creatinine-based equations
285 has been a major concern in clinical practice.^{10, 26-28} Cystatin C, which is produced by all
286 nucleated cells and is not dependent on diet or muscle mass, has been validated as an
287 alternative marker to estimate kidney function. However, Cystatin C levels may be falsely
288 increased in patients with obesity, inflammation, current smoking, and corticosteroid therapy.²⁹⁻³²
289 In 2021, the National Kidney Foundation and the American Society of Nephrology Task Force
290 recommended that clinicians estimate GFR using a combined equation incorporating both
291 cystatin C and serum creatinine.³³ A recent study of 1200 patients with solid tumors who
292 underwent measured GFR found that $eGFR_{CRE}$ overestimated measured GFR, $eGFR_{CYS}$
293 underestimated measured GFR, and that the most accurate and precise eGFR was obtained
294 using the combined equation incorporating both cystatin C and serum creatinine.⁹ We note that
295 risk factors for eGFR underestimation with cystatin C is greater in patients with higher BMI,
296 current and former smokers, low albumin, higher C-reactive protein, and metastatic disease. It is
297 important to note the overlap with the predictors of eGFR discrepancy we identified in this study.
298 Because we lacked measured GFR, we are unable to determine the accuracy of $eGFR_{CRE}$ and
299 $eGFR_{CYS}$, however, we found that when a large eGFR discrepancy exists, patients with cancer
300 are at higher risk of adverse events from renally-cleared medications.

301 Our study demonstrated a higher rate of suprathreshold vancomycin levels in patients
302 with eGFR discrepancy. Vancomycin is a very commonly used intravenous antibiotic in
303 hospitalized patients that is predominantly eliminated by the kidney (>90%). Several studies
304 have demonstrated that vancomycin clearance and target trough achievement may be more
305 accurately predicted by eGFR_{CYS} than eGFR_{CRE}.³⁴⁻³⁸ A previously published quality improvement
306 initiative that included 399 patients found that a vancomycin dosing algorithm using eGFR
307 estimated by both creatinine and cystatin C (N = 135) was more likely to achieve therapeutic
308 vancomycin trough levels (50% vs. 28%, p< 0.001) compared to an algorithm using eGFR_{CRE}
309 alone (N = 264).³⁶ Trimethoprim-sulfamethoxazole is another commonly used antibiotic in the
310 inpatient and outpatient setting. Trimethoprim can have an “amiloride-like” effect by inhibiting
311 potassium secretion in the distal convoluted tubule; patients with impaired kidney function are
312 much more likely to develop clinically significant hyperkalemia when treated with trimethoprim-
313 sulfamethoxazole.³⁹ Hyperkalemia occurred more commonly in patients with eGFR discrepancy
314 compared to the reference group. Digoxin is a cardiac glycoside medication approved to treat
315 atrial fibrillation and congestive heart failure that has a narrow therapeutic index. Digoxin is
316 cleared by the kidneys and its toxicity is dose dependent. There have been conflicting reports
317 regarding use of creatinine versus cystatin C to predict digoxin clearance.⁴⁰⁻⁴⁴ Here, we found
318 that patients with eGFR discrepancy were significantly more likely to have suprathreshold
319 digoxin trough levels compared to the reference group, and both cases of symptomatic digoxin
320 toxicity occurred in patients with eGFR discrepancy. Baclofen is a muscle relaxant that is
321 commonly prescribed in patients with cancer to inhibit the hiccup reflex. Baclofen is primarily
322 eliminated by the kidney. In patients with impaired kidney function, baclofen accumulation can
323 occur after just a single dose, and can lead to profound central nervous system suppression,
324 ranging from encephalopathy, coma, areflexia, hypotension, and cardiac arrest.^{45, 46} Our study
325 showed that symptomatic baclofen toxicity is common in patients with eGFR discrepancy
326 (affecting 25% of patients), whereas no events occurred in the reference group, suggesting that

327 the eGFR_{CYS} should be considered when prescribing baclofen to patients with cancer. To the
328 best of our knowledge, this is the first study to evaluate eGFR_{CYS} and eGFR_{CRE} in patients
329 receiving baclofen. Taken together, our findings suggest that relying on creatinine-based eGFR
330 alone for medication dosing may be inadequate in patients with cancer and highlights the need
331 to consider eGFR_{CYS} as well.

332 Finally, consistent with prior knowledge that incorporation of cystatin C adds precision to
333 the eGFR equation in patients with malnutrition, sarcopenia, and cirrhosis,^{9, 47, 48} we note that
334 hypoalbuminemia and anemia are important predictors of eGFR discrepancy in patients with
335 cancer. It is likely that these laboratory abnormalities that signify chronic illness are associated
336 with cancer-related sarcopenia. Future prospective studies that include measured GFR are
337 needed to validate this finding. In addition, we found that eGFR discrepancy is associated with
338 significantly higher 30-day mortality even after adjustment for demographics, comorbidities,
339 baseline laboratory studies, and medication use. Although higher serum creatinine and cystatin
340 C have each been shown to be associated with increased mortality in multiple clinical
341 settings,⁴⁹⁻⁵⁴ our finding suggests that discrepancy between creatinine and cystatin C, in addition
342 to the absolute values of either marker, adds further information and potentially serves as an
343 independent predictor of death.

344 Our study has several limitations. First, cystatin C was only available on select patients,
345 where it has been ordered as a part of routine care. Since cystatin C is not routinely used in
346 clinical practice, our population was likely enriched for patients in whom clinicians suspected an
347 eGFR discrepancy or kidney injury might exist, this likely an overestimate of the rate of eGFR
348 discrepancy in the oncology population in general. However, the selection bias should be
349 balanced between the eGFR discrepancy group and the reference group, which preserves the
350 validity of comparison of medication-related adverse events between the two groups. Second,
351 we only used a one-time assessment of creatinine and cystatin C, which may not reflect a
352 steady state at the time of measurement. Third, we were not able to determine cancer stage

353 from our dataset, which may be an important non-GFR determinant of cystatin C and
354 creatinine.^{55, 56} Fourth, it is possible that clinician knowledge of the eGFR_{CYS} could have
355 influenced medication dosing; however, such practice would have biased our results toward the
356 null. Accordingly, the magnitude of association between eGFR discrepancy and medication-
357 related adverse events that we report here is likely an underestimate. Finally, our study lacks
358 gold standard GFR measurement given the retrospective design; however, comparing adverse
359 outcomes of renally-dosed medications serves as surrogate marker for accuracy of eGFR.

360 In conclusion, we found that a >30% eGFR discrepancy is common in patients with
361 cancer and is associated with an increase in adverse events related to commonly used, renally-
362 cleared medications. Future prospective studies are needed to improve and personalize the
363 approach to GFR estimation and medication dosing in patients with cancer.

364 **References:**

- 365
- 366 1. Soveri I, Berg UB, Bjork J, Elinder CG, Grubb A, Mejare I, Sterner G, Back SE, Group SGR.
367 Measuring GFR: a systematic review. *Am J Kidney Dis.* 2014;64(3):411-24. Epub 20140517. doi:
368 10.1053/j.ajkd.2014.04.010. PubMed PMID: 24840668.
 - 369 2. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to
370 estimate glomerular filtration rate from serum creatinine: a new prediction equation.
371 Modification of Diet in Renal Disease Study Group. *Ann Intern Med.* 1999;130(6):461-70. doi:
372 10.7326/0003-4819-130-6-199903160-00002. PubMed PMID: 10075613.
 - 373 3. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente
374 F, Chronic Kidney Disease Epidemiology C. Using standardized serum creatinine values in the
375 modification of diet in renal disease study equation for estimating glomerular filtration rate.
376 *Ann Intern Med.* 2006;145(4):247-54. doi: 10.7326/0003-4819-145-4-200608150-00004.
377 PubMed PMID: 16908915.
 - 378 4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine.
379 *Nephron.* 1976;16(1):31-41. doi: 10.1159/000180580. PubMed PMID: 1244564.
 - 380 5. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A,
381 Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutierrez OM, Kalil R,
382 Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E,
383 Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS,
384 Chronic Kidney Disease Epidemiology C. New Creatinine- and Cystatin C-Based Equations to
385 Estimate GFR without Race. *N Engl J Med.* 2021;385(19):1737-49. Epub 20210923. doi:
386 10.1056/NEJMoa2102953. PubMed PMID: 34554658; PMCID: PMC8822996.
 - 387 6. Shafi T, Zhu X, Lirette ST, Rule AD, Mosley T, Butler KR, Hall ME, Vaitla P, Wynn JJ, Tio
388 MC, Dossabhoy NR, Guallar E, Butler J. Quantifying Individual-Level Inaccuracy in Glomerular
389 Filtration Rate Estimation : A Cross-Sectional Study. *Ann Intern Med.* 2022;175(8):1073-82.
390 Epub 20220705. doi: 10.7326/M22-0610. PubMed PMID: 35785532.
 - 391 7. Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, Froissart M, Kusek JW, Zhang
392 YL, Coresh J, Levey AS. Factors other than glomerular filtration rate affect serum cystatin C
393 levels. *Kidney Int.* 2009;75(6):652-60. Epub 20081231. doi: 10.1038/ki.2008.638. PubMed
394 PMID: 19119287; PMCID: PMC4557800.
 - 395 8. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J,
396 Van Lente F, Zhang YL, Coresh J, Levey AS, Investigators C-E. Estimating glomerular filtration
397 rate from serum creatinine and cystatin C. *N Engl J Med.* 2012;367(1):20-9. doi:
398 10.1056/NEJMoa1114248. PubMed PMID: 22762315; PMCID: PMC4398023.
 - 399 9. Costa ESVT, Gil LA, Jr., Inker LA, Caires RA, Costalonga E, Coura-Filho G, Sapienza MT,
400 Castro G, Jr., Estevez-Diz MD, Zanetta DMT, Antonangelo L, Marcal L, Tighiouart H, Miao S,
401 Mathew P, Levey AS, Burdmann EA. A prospective cross-sectional study estimated glomerular
402 filtration rate from creatinine and cystatin C in adults with solid tumors. *Kidney Int.*
403 2022;101(3):607-14. Epub 20220112. doi: 10.1016/j.kint.2021.12.010. PubMed PMID:
404 35032521.
 - 405 10. Williams GR, Dunne RF, Giri S, Shachar SS, Caan BJ. Sarcopenia in the Older Adult With
406 Cancer. *J Clin Oncol.* 2021;39(19):2068-78. Epub 2021/05/28. doi: 10.1200/jco.21.00102.
407 PubMed PMID: 34043430; PMCID: PMC8260902 DunneConsulting or Advisory Role: Exelixis

- 408 Smith GiriHonoraria: CareVive, OncliveResearch Funding: Carevive Systems, Pack Health
409 Shlomit S. ShacharConsulting or Advisory Role: Novartis, Roche, Pfizer, LillyTravel,
410 Accommodations, Expenses: Pfizer, RocheNo other potential conflicts of interest were
411 reported.
- 412 11. Chute DF, Zhao S, Strohbehn IA, Rusibamayila N, Seethapathy H, Lee M, Zubiri L, Gupta
413 S, Leaf DE, Rahma O, Drobni ZD, Neilan TG, Reynolds KL, Sise ME. Incidence and Predictors of
414 CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors. *Am J*
415 *Kidney Dis.* 2022;79(1):134-7. Epub 20210624. doi: 10.1053/j.ajkd.2021.05.012. PubMed PMID:
416 34174363; PMCID: PMC8855486.
- 417 12. Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, Cortazar FB, Leaf DE,
418 Mooradian MJ, Villani AC, Sullivan RJ, Reynolds K, Sise ME. The Incidence, Causes, and Risk
419 Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. *Clin J Am*
420 *Soc Nephrol.* 2019;14(12):1692-700. Epub 20191031. doi: 10.2215/CJN.00990119. PubMed
421 PMID: 31672794; PMCID: PMC6895474.
- 422 13. Inker LA, Eckfeldt J, Levey AS, Leiendecker-Foster C, Rynders G, Manzi J, Waheed S,
423 Coresh J. Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin
424 C equations for estimating GFR with standardized serum cystatin C values. *Am J Kidney Dis.*
425 2011;58(4):682-4. Epub 20110819. doi: 10.1053/j.ajkd.2011.05.019. PubMed PMID: 21855190;
426 PMCID: PMC4421875.
- 427 14. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente
428 F, Bruce RD, 3rd, Zhang YL, Greene T, Levey AS. Estimating GFR using serum cystatin C alone
429 and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. *Am J*
430 *Kidney Dis.* 2008;51(3):395-406. doi: 10.1053/j.ajkd.2007.11.018. PubMed PMID: 18295055;
431 PMCID: PMC2390827.
- 432 15. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, Griffith KE,
433 Hemmelgarn BR, Iseki K, Lamb EJ. Kidney Disease: Improving Global Outcomes (KDIGO) CKD
434 Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of
435 chronic kidney disease. *Kidney international supplements.* 2013;3(1):1-150.
- 436 16. Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, Mendu ML,
437 Miller WG, Moxey-Mims MM, Roberts GV, St Peter WL, Warfield C, Powe NR. A Unifying
438 Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the
439 Inclusion of Race in Diagnosing Kidney Disease. *J Am Soc Nephrol.* 2021;32(12):2994-3015. Epub
440 2021/09/25. doi: 10.1681/asn.2021070988. PubMed PMID: 34556489; PMCID: PMC8638402.
- 441 17. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-
442 Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro BM. Therapeutic monitoring of
443 vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: A revised
444 consensus guideline and review by the American Society of Health-System Pharmacists, the
445 Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the
446 Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm.* 2020;77(11):835-64. doi:
447 10.1093/ajhp/zxaa036. PubMed PMID: 32191793.
- 448 18. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-
449 induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and
450 20 milligrams per liter. *Antimicrob Agents Chemother.* 2013;57(2):734-44. Epub 20121119. doi:
451 10.1128/AAC.01568-12. PubMed PMID: 23165462; PMCID: PMC3553731.

- 452 19. Tuon FF, Romero R, Gasparetto J, Cieslinski J. Vancomycin trough level and loading dose.
453 Infect Drug Resist. 2018;11:2393-6. Epub 20181123. doi: 10.2147/IDR.S184897. PubMed PMID:
454 30538506; PMCID: PMC6260187.
- 455 20. Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure.
456 Kidney Int. 2010;77(9):760-4. Epub 20100224. doi: 10.1038/ki.2010.35. PubMed PMID:
457 20182415.
- 458 21. Zonozi R, Wu A, Shin JI, Secora A, Coresh J, Inker LA, Chang AR, Grams ME. Elevated
459 Vancomycin Trough Levels in a Tertiary Health System: Frequency, Risk Factors, and Prognosis.
460 Mayo Clin Proc. 2019;94(1):17-26. doi: 10.1016/j.mayocp.2018.08.034. PubMed PMID:
461 30611444; PMCID: PMC6341482.
- 462 22. Chen KS, Bullard MJ, Chien YY, Lee SY. Baclofen toxicity in patients with severely
463 impaired renal function. Ann Pharmacother. 1997;31(11):1315-20. doi:
464 10.1177/106002809703101108. PubMed PMID: 9391686.
- 465 23. Cheong M, Lee J, Lee TY, Kim SB. Prevalence and risk factors of baclofen neurotoxicity in
466 patients with severely impaired renal function. Nefrologia (Engl Ed). 2020;40(5):543-51. Epub
467 20200724. doi: 10.1016/j.nefro.2020.03.004. PubMed PMID: 32718544.
- 468 24. Critchley JA, Critchley LA. Digoxin toxicity in chronic renal failure: treatment by multiple
469 dose activated charcoal intestinal dialysis. Hum Exp Toxicol. 1997;16(12):733-5. doi:
470 10.1177/096032719701601207. PubMed PMID: 9429088.
- 471 25. Aronson JK, Grahame-Smith DG. Altered distribution of digoxin in renal failure--a cause
472 of digoxin toxicity? Br J Clin Pharmacol. 1976;3(6):1045-51. doi: 10.1111/j.1365-
473 2125.1976.tb00356.x. PubMed PMID: 22216528; PMCID: PMC1428967.
- 474 26. Hudson JQ, Nolin TD. Pragmatic Use of Kidney Function Estimates for Drug Dosing: The
475 Tide Is Turning. Adv Chronic Kidney Dis. 2018;25(1):14-20. Epub 2018/03/04. doi:
476 10.1053/j.ackd.2017.10.003. PubMed PMID: 29499882.
- 477 27. Yoshida S, Suda G, Ohara M, Fu Q, Yang Z, Hosoda S, Kimura M, Akinori K, Tokuchi Y,
478 Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K,
479 Ogawa K, Maehara O, Ohnishi S, Sakamoto N. Frequency and Characteristics of Overestimated
480 Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia.
481 Nutrients. 2021;13(7). Epub 2021/08/11. doi: 10.3390/nu13072415. PubMed PMID: 34371925;
482 PMCID: PMC8308887.
- 483 28. Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for
484 survival and complications of cancer therapy. Ann Oncol. 2018;29(suppl_2):ii1-ii9. Epub
485 2018/03/06. doi: 10.1093/annonc/mdx810. PubMed PMID: 29506228.
- 486 29. Shlipak MG, Matsushita K, Arnlov J, Inker LA, Katz R, Polkinghorne KR, Rothenbacher D,
487 Sarnak MJ, Astor BC, Coresh J, Levey AS, Gansevoort RT, Consortium CKDP. Cystatin C versus
488 creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932-43.
489 doi: 10.1056/NEJMoa1214234. PubMed PMID: 24004120; PMCID: PMC3993094.
- 490 30. Levey AS, Titan SM, Powe NR, Coresh J, Inker LA. Kidney Disease, Race, and GFR
491 Estimation. Clin J Am Soc Nephrol. 2020;15(8):1203-12. Epub 20200511. doi:
492 10.2215/CJN.12791019. PubMed PMID: 32393465; PMCID: PMC7409747.
- 493 31. Ebert N, Shlipak MG. Cystatin C is ready for clinical use. Curr Opin Nephrol Hypertens.
494 2020;29(6):591-8. doi: 10.1097/MNH.0000000000000638. PubMed PMID: 32868529.

- 495 32. Shlipak MG, Tummalapalli SL, Boulware LE, Grams ME, Ix JH, Jha V, Kengne AP, Madero
496 M, Mihaylova B, Tangri N, Cheung M, Jadoul M, Winkelmayer WC, Zoungas S, Conference P. The
497 case for early identification and intervention of chronic kidney disease: conclusions from a
498 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int.*
499 2021;99(1):34-47. Epub 20201027. doi: 10.1016/j.kint.2020.10.012. PubMed PMID: 33127436.
- 500 33. Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, Mendu ML,
501 Miller WG, Moxey-Mims MM, Roberts GV, St Peter WL, Warfield C, Powe NR. A Unifying
502 Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the
503 Inclusion of Race in Diagnosing Kidney Disease. *J Am Soc Nephrol.* 2021. Epub 20210923. doi:
504 10.1681/ASN.2021070988. PubMed PMID: 34556489; PMCID: PMC8638402.
- 505 34. Oh Y, Park S, Park E, Lee J, Lee H, Kim J, Cho J. Correlation between vancomycin
506 clearance and cystatin C-based glomerular filtration rate in paediatric patients. *Br J Clin*
507 *Pharmacol.* 2021;87(8):3190-6. Epub 20210126. doi: 10.1111/bcp.14733. PubMed PMID:
508 33496976.
- 509 35. Teaford HR, Stevens RW, Rule AD, Mara KC, Kashani KB, Lieske JC, O'Horo J, Barreto EF.
510 Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a
511 Retrospective Cohort Study of Hospitalized Patients. *Antimicrob Agents Chemother.* 2020;65(1).
512 Epub 20201216. doi: 10.1128/AAC.01487-20. PubMed PMID: 33106257; PMCID: PMC7927827.
- 513 36. Frazee E, Rule AD, Lieske JC, Kashani KB, Barreto JN, Virk A, Kuper PJ, Dierkhising RA,
514 Leung N. Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement
515 Project. *Am J Kidney Dis.* 2017;69(5):658-66. Epub 20170125. doi: 10.1053/j.ajkd.2016.11.016.
516 PubMed PMID: 28131530.
- 517 37. Frazee EN, Rule AD, Herrmann SM, Kashani KB, Leung N, Virk A, Voskoboev N, Lieske JC.
518 Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized
519 patients: a cohort study. *Crit Care.* 2014;18(3):R110. Epub 20140529. doi: 10.1186/cc13899.
520 PubMed PMID: 24887089; PMCID: PMC4075252.
- 521 38. Barreto EF, Rule AD, Murad MH, Kashani KB, Lieske JC, Erwin PJ, Steckelberg JM, Gajic O,
522 Reid JM, Kane-Gill SL. Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine:
523 A Systematic Review. *Mayo Clin Proc.* 2019;94(3):500-14. Epub 20190131. doi:
524 10.1016/j.mayocp.2018.08.002. PubMed PMID: 30713050.
- 525 39. Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with
526 trimethoprim-sulfamethoxazole. *Ann Intern Med.* 1996;124(3):316-20. doi: 10.7326/0003-
527 4819-124-3-199602010-00006. PubMed PMID: 8554227.
- 528 40. Hallberg P, Melhus H, Hansson LO, Larsson A. Cystatin C vs creatinine as markers of
529 renal function in patients on digoxin treatment. *Ups J Med Sci.* 2004;109(3):247-53. doi:
530 10.3109/2000-1967-087. PubMed PMID: 15508527.
- 531 41. Nakamura T, Ioroi T, Sakaeda T, Horinouchi M, Hayashi N, Saito K, Kosaka M, Okamura
532 N, Kadoyama K, Kumagai S, Okumura K. Serum cystatin C levels to predict serum concentration
533 of digoxin in Japanese patients. *Int J Med Sci.* 2006;3(3):92-6. Epub 20060517. doi:
534 10.7150/ijms.3.92. PubMed PMID: 16761077; PMCID: PMC1475426.
- 535 42. O'Riordan S, Ouldred E, Brice S, Jackson SH, Swift CG. Serum cystatin C is not a better
536 marker of creatinine or digoxin clearance than serum creatinine. *Br J Clin Pharmacol.*
537 2002;53(4):398-402. doi: 10.1046/j.1365-2125.2002.01549.x. PubMed PMID: 11966673;
538 PMCID: PMC1874275.

- 539 43. Garcia A, Hermida J, Tutor JC. Estimation of the glomerular filtration rate from serum
540 creatinine and cystatin C with regard to therapeutic digoxin monitoring. *J Clin Pharmacol.*
541 2007;47(11):1450-5. Epub 20070813. doi: 10.1177/0091270007305503. PubMed PMID:
542 17698593.
- 543 44. Salek T, Vodicka M, Griva M. Cystatin C may be better than creatinine for digoxin dosing
544 in older adults with atrial fibrillation. *J Clin Lab Anal.* 2020;34(10):e23427. Epub 20200617. doi:
545 10.1002/jcla.23427. PubMed PMID: 32716587; PMCID: PMC7595907.
- 546 45. Leung NY, Whyte IM, Isbister GK. Baclofen overdose: Defining the spectrum of toxicity.
547 *Emergency Medicine Australasia.* 2006;18(1):77-82. doi: [https://doi.org/10.1111/j.1742-](https://doi.org/10.1111/j.1742-6723.2006.00805.x)
548 [6723.2006.00805.x](https://doi.org/10.1111/j.1742-6723.2006.00805.x).
- 549 46. Norouzi S, Farouk SS, Sparks MA. Back off baclofen when the kidneys don't work. *Kidney*
550 *Int.* 2020;98(4):829-31. doi: 10.1016/j.kint.2020.05.026. PubMed PMID: 32998812.
- 551 47. Mindikoglu AL, Dowling TC, Weir MR, Seliger SL, Christenson RH, Magder LS.
552 Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C
553 equation for estimating kidney function in cirrhosis. *Hepatology.* 2014;59(4):1532-42. doi:
554 <https://doi.org/10.1002/hep.26556>.
- 555 48. Mindikoglu AL, Opekun AR, Mitch WE, Magder LS, Christenson RH, Dowling TC, Weir
556 MR, Seliger SL, Howell CD, Raufman JP, Rana A, Goss JA, Khaderi SA, Vierling JM. Cystatin C Is a
557 Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. *Dig Dis Sci.*
558 2018;63(3):665-75. Epub 2018/02/03. doi: 10.1007/s10620-017-4897-z. PubMed PMID:
559 29392554; PMCID: PMC5994910.
- 560 49. Krolewski AS, Warram JH, Forsblom C, Smiles AM, Thorn L, Skupien J, Harjutsalo V,
561 Stanton R, Eckfeldt JH, Inker LA, Groop PH. Serum concentration of cystatin C and risk of end-
562 stage renal disease in diabetes. *Diabetes Care.* 2012;35(11):2311-6. Epub 20120730. doi:
563 10.2337/dc11-2220. PubMed PMID: 22851596; PMCID: PMC3476893.
- 564 50. Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA,
565 Satterfield S, Cummings SR, Newman AB, Fried LF. Cystatin C and mortality risk in the elderly:
566 the health, aging, and body composition study. *J Am Soc Nephrol.* 2006;17(1):254-61. Epub
567 20051102. doi: 10.1681/ASN.2005050545. PubMed PMID: 16267155.
- 568 51. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality,
569 cardiovascular events, and incident heart failure among persons with coronary heart disease:
570 data from the Heart and Soul Study. *Circulation.* 2007;115(2):173-9. Epub 20061226. doi:
571 10.1161/CIRCULATIONAHA.106.644286. PubMed PMID: 17190862; PMCID: PMC2771187.
- 572 52. Vigil A, Condes E, Vigil L, Gallar P, Oliet A, Ortega O, Rodriguez I, Ortiz M, Herrero JC,
573 Mon C, Cobo G, Jimenez J. Cystatin C as a predictor of mortality and cardiovascular events in a
574 population with chronic kidney disease. *Int J Nephrol.* 2014;2014:127943. Epub 20140211. doi:
575 10.1155/2014/127943. PubMed PMID: 24672725; PMCID: PMC3942201.
- 576 53. Helmersson-Karlqvist J, Lipcsey M, Arnlov J, Bell M, Ravn B, Dardashti A, Larsson A.
577 Cystatin C predicts long term mortality better than creatinine in a nationwide study of intensive
578 care patients. *Sci Rep.* 2021;11(1):5882. Epub 20210315. doi: 10.1038/s41598-021-85370-8.
579 PubMed PMID: 33723337; PMCID: PMC7961058.
- 580 54. Bell M, Granath F, Martensson J, Lofberg E, Ekblom A, Martling CR, King. Cystatin C is
581 correlated with mortality in patients with and without acute kidney injury. *Nephrol Dial*

582 Transplant. 2009;24(10):3096-102. Epub 20090425. doi: 10.1093/ndt/gfp196. PubMed PMID:
583 19395727.

584 55. Demirtaş S, Akan O, Can M, Elmali E, Akan H. Cystatin C can be affected by nonrenal
585 factors: a preliminary study on leukemia. Clin Biochem. 2006;39(2):115-8. Epub 2005/12/13.
586 doi: 10.1016/j.clinbiochem.2005.10.009. PubMed PMID: 16337174.

587 56. Oc MA, Demir H, Cekmen MB, Isgoren S, Gorur GD, Bilgili U. Correlation of Cystatin-C
588 and radionuclidic measurement method of glomerular filtration rate in patients with lung
589 cancer receiving cisplatin treatment. Ren Fail. 2014;36(7):1043-50. Epub 2014/05/23. doi:
590 10.3109/0886022x.2014.918813. PubMed PMID: 24846459.

591
592


593 **Table 1. Patient Characteristics**

	Overall	eGFR discrepancy	Reference group
Covariates	N=1988	N=579	N=1409
Age	66 (14.1)	68 (14.3)	65(14.0)
Female Sex	965 (48.5)	293 (50.6)	672 (47.7)
Race/Ethnicity			
White	1555 (78.2)	467 (80.7)	1088 (77.2)
Black	184 (9.3)	43 (7.4)	141 (10.0)
Hispanic	89 (4.5)	27 (4.7)	62 (4.4)
Asian	72 (3.6)	20 (3.5)	52 (3.7)
Other	88 (4.4)	22 (3.8)	66 (4.7)
Body Mass Index (kg/m²)			
Underweight (<18.5)	54 (3.6)	25 (6.1)	29 (2.6)
Normal (18.5 - 24.9)	442 (29.4)	126 (30.8)	316 (28.9)
Overweight (25 - 29.9)	515 (34.2)	114 (27.9)	401 (36.6)
Obese (≥30)	493 (32.8)	144 (35.2)	349 (31.9)
Comorbidities			
Hypertension	1600 (80.5)	507 (87.6)	1093 (77.6)
Coronary Artery Disease	987 (49.6)	377 (65.1)	610 (43.3)
Diabetes Mellitus	1008 (50.7)	393 (67.9)	615 (43.6)
Cirrhosis	105 (5.3)	61 (10.5)	44 (3.1)
Human Immunodeficiency Virus	82 (4.1)	20 (3.5)	62 (4.4)
Smoking	806 (40.5)	266 (45.9)	540 (38.3)
Malnutrition	275 (13.8)	97 (16.8)	178 (12.6)
Thyroid disease	503 (25.3)	177 (30.6)	326 (23.1)
Chronic kidney disease			
eGFR 30 - 50 mL/min per 1.72m ²	804 (40.4)	254 (43.9)	550 (39.0)
eGFR < 30 mL/min per 1.73m ²	514 (25.8)	211 (36.5)	303 (21.5)
Medication Use			
ACEi/ARB	1128 (56.7)	345 (59.6)	783 (55.6)
Proton Pump Inhibitors	1291 (64.9)	441 (76.2)	850 (60.3)
Diuretics	1282 (64.5)	474 (81.9)	808 (57.3)
Corticosteroids*	393 (19.8)	207 (35.8)	186 (13.2)
Labs			
Serum Creatinine (mg/dL)	1.62 (1.03)	1.44 (0.75)	1.70 (1.12)
Serum Cystatin C (mg/L)	1.82 (0.97)	2.37 (1.03)	1.59 (0.84)
eGFR _{CRE-CYS} (mL/min per 1.73m ²)	51 (28)	41 (22)	55 (29)
Serum Albumin (g/dL)			
<3.0	297 (15.5)	198 (34.6)	99 (7.4)
3.0-3.49	187 (9.8)	96 (16.8)	91 (6.8)
3.5-3.9	280 (14.6)	111 (19.4)	169 (12.6)
≥4.0	1152 (60.1)	168 (29.3)	984 (73.3)
Blood Urea Nitrogen (mg/dL)			
≤17	501 (25.2)	99 (17.1)	402 (28.6)
17-25	526 (26.5)	107 (18.5)	419 (29.8)
25-39	482 (24.3)	147 (25.4)	335 (23.8)
>39	478 (24.1)	226 (39.0)	252 (17.9)
Hemoglobin (g/dL)			
≤10.0	597 (30.0)	324 (56.0)	273(19.4)
10 -11.9	505 (25.4)	138 (23.8)	367 (26.0)
≥12.0	886 (44.6)	117 (20.2)	769 (54.6)

594 **Table 1.** eGFR discrepancy was defined as eGFR_{CYS} more than 30% lower than eGFR_{CRE}. Count and
595 percent or mean and standard deviations are shown. Body mass index was missing for 479 participants
596 (24%), serum albumin was missing for 72 participants (3.6%), and hemoglobin was missing for 46
597 participants (2.3%). The remaining data was complete. Chronic kidney disease was staged using the
598 eGFR_{CRE-CYS}. Abbreviations: eGFR_{CRE-CYS} = estimated Glomerular Filtration Rate using creatinine and
599 cystatin C equation, ACEi/ARB = Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker.

600
601
602


Figure 1. Patient flow



603
604
605
606
607
608
609
610

Figure 1. Patient flow. Exposure to each medication was determined by an active prescription within 90 days of the baseline date. *Shows the analyzed sample for each medication. Abbreviations: eGFR_{CRE} = creatinine-based estimated glomerular filtration rate, eGFR_{CYS} = cystatin c-based estimated glomerular filtration rate.


611 **Figure 2. Predictors of eGFR discrepancy**




612 **Figure 2. Forrest plot showing adjusted odds ratios.** Logistic regression models were used to
 613 estimate the association between baseline characteristics and the eGFR discrepancy (eGFR_{CYS} > 30%
 614 lower than eGFR_{CRE}) in patients with cancer. The unadjusted and adjusted models are also shown in
 615 **Supplemental Table 2.** Abbreviations: eGFR_{CRE-CYS} = estimated Glomerular Filtration Rate calculated
 616 using the 2021 race-free combined serum creatinine and cystatin C equation
 617

618 **Figure 3. Rate of eGFR discrepancy by albumin and hemoglobin levels**
619

3A) Rate of eGFR discrepancy by albumin level



3B) Rate of eGFR discrepancy by hemoglobin level




620
621
622
623
624
625
626
627
628


Figure 3. eGFR discrepancy defined by $eGFR_{CYS} > 30\%$ lower than $eGFR_{CRE}$ shown with light blue bars, and severe eGFR discrepancy ($eGFR_{CYS} > 50\%$ lower than $eGFR_{CRE}$ and $eGFR_{CYS} < 30\text{mL}/\text{min}/1.73\text{m}^2$) shown with dark blue bars become more common in patients with worsening hypoalbuminemia (3A) and anemia (3B).

629 **Figure 4. Rate of supratherapeutic vancomycin levels and trimethoprim-**
630 **sulfamethoxazole-related hyperkalemia in patients with eGFR discrepancy**
631

4A. Vancomycin trough levels



4B. Peak potassium levels on Trimethoprim-sulfamethoxazole




632 ■ Reference Group ■ >30% Discrepancy ■ Severe Discrepancy

633 **Figure 4A.** Highest trough vancomycin levels obtained within 30 days of starting vancomycin in
634 patients with eGFR discrepancy (eGFR_{CYS} more than 30% lower than eGFR_{CRE}), severe eGFR
635 discrepancy (eGFR_{CYS} more than 50% lower than eGFR_{CRE} and eGFR_{CYS} < 30mL/min/1.73m²),
636 and the reference group. We excluded any vancomycin level obtained less than 6 hours after
637 the last administered vancomycin dose. **Figure 4B.** Rate of Grade 2 or 3 hyperkalemia in
638 patients receiving trimethoprim-sulfamethoxazole.


639
640
641
642

643 **Figure 5. Rate of baclofen toxicity and digoxin toxicity in patients with eGFR discrepancy**
644



645
646
647 **Figure 5A.** Rate of baclofen toxicity in patients with eGFR discrepancy, severe eGFR,
648 discrepancy and the reference group. **Figure 5B.** Rate of supratherapeutic digoxin level defined
649 by $>2.0\mu\text{g/dL}$. Both cases of clinical digoxin toxicity occurred in patients with severe eGFR
650 discrepancy (eGFR_{CYS} more than 50% lower than eGFR_{CRE} and $\text{eGFR}_{\text{CYS}} < 30\text{mL/min/1.73m}^2$).
651 There were no cases of supratherapeutic digoxin levels or digoxin toxicity in the reference
652 group.
653
654

655 **Figure 6. Kaplan-Meier curve of 30-day survival**




Number at risk

Reference	1409	1318	1300	1285	1280	1270	1262
eGFR discrepancy	579	519	494	474	453	435	425

656
 657
 658 **Figure 6.** Survival analysis using Kaplan Meier method comparing 30-day survival between
 659 reference group and those who had eGFR discrepancy. Unadjusted and adjusted model is
 660 shown in Supplemental Table 7.
 661

662
 663
 664
 665
 666
 667
 668
 669
 670
 671
 672
 673
 674
 675


676 **Supplemental Figure 1. Scatter plot of creatinine-based and cystatin C-based eGFR, and**
677 **distribution of eGFR difference**
678



679
680
681 **Supplemental Figure 1. Scatterplot showing distribution of eGFR_{CRE} and eGFR_{CYS} among**
682 **patients with cancer (S1A); the blue line is the line of equality. Figure S1B. A histogram and**
683 **superimposed density curve showing the distribution of eGFR difference defined by eGFR_{CYS}**
684 **minus eGFR_{CRE}. The red dotted line signifies equivalence between eGFR_{CRE} and eGFR_{CYS}.**
685 Abbreviations: IQR, interquartile range
686
687
688
689

690 **Supplemental Figure 2. Scatter plot of creatinine-based and cystatin C-based eGFR by**
691 **albumin and hemoglobin levels.**

692



693

694

695 **Supplemental Figure 2.** Scatterplot showing distribution of eGFRs among patients with cancer
696 stratified by different albumin levels (S2A) and hemoglobin levels (S2B) as shown. The identity
697 line (line of equality) is shown in blue.


698

699

700

701


702 **Supplemental Figure 3.** Rate of eGFR discrepancies by cancer type
703




704 **Supplemental Figure 3.** Rate of eGFR discrepancy and severe eGFR discrepancy by cancer
705 type. eGFR discrepancy is defined by an $eGFR_{CYS}$ more than 30% lower than $eGFR_{CRE}$. Severe
706 eGFR discrepancy was defined as an $eGFR_{CYS}$ more than 50% lower than $eGFR_{CRE}$ and
707 $eGFR_{CYS} < 30\text{mL}/\text{min}/1.73\text{m}^2$.
708
709
710
711
712

713 **Supplemental Figure 4.** Changes in potassium levels among patients who received
714 trimethoprim-sulfamethoxazole.
715

S4A. Mean change in potassium levels



S4B. Rate of ≥ 0.5 mEq/L rise in potassium levels



■ Reference Group ■ >30% Discrepancy ■ Severe Discrepancy

716 **Supplemental Figure S4A.** Mean change in potassium levels with standard deviations among
717 trimethoprim-sulfamethoxazole recipients; error bars show standard deviation. **S4B.** Rate of
718 ≥ 0.5 mEq/L rise in potassium levels among trimethoprim-sulfamethoxazole recipients. eGFR
719 discrepancy is defined by an $eGFR_{CYS}$ more than 30% lower than $eGFR_{CRE}$. Severe eGFR
720 discrepancy was defined as an $eGFR_{CYS}$ more than 50% lower than $eGFR_{CRE}$ and $eGFR_{CYS} <$
721 $30 \text{ mL/min/1.73m}^2$.
722
723

724
725
726
727

728 **Supplemental Table 1. Cancer type**

729

	Overall	eGFR discrepancy	Reference group
	N=1988	N=579	N=1409
Cancer types*			
Urothelial	92 (4.6)	23 (4.0)	69 (4.9)
Brain	40 (2.0)	10 (1.7)	30 (2.1)
Breast	228 (11.5)	32 (5.5)	196 (13.9)
Gastrointestinal	177 (8.9)	69 (11.9)	108 (7.7)
Gynecologic	141 (7.1)	36 (6.2)	105 (7.5)
Head & Neck	50 (2.5)	15 (2.6)	35 (2.5)
Leukemia	129 (6.5)	63 (10.9)	66 (4.7)
Lymphoma	123 (6.2)	54 (9.3)	69 (4.9)
Melanoma	29 (1.5)	13 (2.2)	16 (1.1)
Prostate	147 (7.4)	31 (5.4)	116 (8.2)
Kidney	162 (8.1)	37 (6.4)	125 (8.9)
Sarcoma	4 (0.2)	1 (0.2)	3 (0.2)
Testicular	1 (0.1)	0 (0.0)	1 (0.1)
Thoracic	114 (5.7)	43 (7.4)	71 (5.0)
Thyroid	43 (2.2)	11 (1.9)	32 (2.3)
Skin (Other)	298 (15.0)	71 (12.3)	227 (16.1)

730

731

732 **Supplemental Table 1.** Cancer type was determined by the most commonly appearing cancer-

733 related diagnosis code prior to the baseline date. eGFR discrepancy is defined by an eGFR_{CYS}

734 more than 30% lower than eGFR_{CRE}.

735

736

737

738

739 **Supplemental Table 2. Predictors of eGFR_{CYS} more than 30% lower than eGFR_{CRE}**

Covariates	eGFR _{CYS} >30% lower than eGFR _{CRE}					
	Univariable			Multivariable		
	OR	95% CI	p-value	Adj OR	95% CI	p-value
Age (per 10 years)	1.12	1.05, 1.20	0.001	1.03	0.93, 1.13	0.60
Male Sex	1.12	0.93, 1.36	0.24	1.04	0.82, 1.31	0.77
White Race	1.23	0.97, 1.57	0.092	1.54	0.16, 2.05	0.003
Body mass index						
Normal (18.5 - 24.9)	REF	—		—	—	
Under weight (<18.5)	2.15	1.21, 3.81	0.009	1.80	0.91, 3.52	0.087
Overweight (25 - 29.9)	0.99	0.77, 1.27	0.918	1.29	0.95, 1.71	0.113
Obese (≥ 30)	1.03	0.78, 1.36	0.846	1.51	1.07, 2.13	0.018
Smoking	1.37	1.12, 1.66	0.002	0.90	0.71, 1.15	0.40
Comorbidities						
Hypertension	2.04	1.55, 2.70	<0.001	0.97	0.66, 1.42	0.87
Coronary Artery Disease	2.44	2.00, 2.99	<0.001	1.27	0.98, 1.66	0.075
Diabetes Mellitus	2.73	2.23, 3.35	<0.001	1.28	0.99, 1.66	0.064
Cirrhosis	3.65	2.45, 5.48	<0.001	1.82	1.14, 2.95	0.013
Human Immunodeficiency Virus	0.78	0.45, 1.28	0.336			
Malnutrition	1.39	1.06, 1.82	0.016	0.93	0.67, 1.29	0.69
Thyroid disease	1.46	1.18, 1.81	<0.001	1.16	0.89, 1.50	0.27
Medication Use*						
ACEi/ARB	1.18	0.97, 1.44	0.101			
Proton Pump Inhibitors	2.10	1.69, 2.62	<0.001	0.97	0.74, 1.28	0.83
Diuretics	3.36	2.66, 4.27	<0.001	1.68	1.23, 2.30	0.001
Corticosteroids	3.66	2.91, 4.61	<0.001	1.70	1.28, 2.24	<0.001
Labs						
eGFR _{CRE-CYS}	0.98	0.98, 0.98	<0.001	0.99	0.99, 1.00	0.003
Albumin (g/dL)						
≥4.0	REF	—		—	—	
3.0 to <4.0	4.8	3.77, 6.13	<0.001	2.557	1.93, 3.42	<0.001
<3.0	12.1	9.06, 16.2	<0.001	5.48	3.84, 7.86	<0.001
Hemoglobin (g/dL)						
≥12.0	REF	—		—	—	
10.0 to <12.0	2.47	1.88, 3.26	<0.001	1.53	1.12, 2.08	0.007
≤10.0	7.8	6.08, 10.1	<0.001	2.17	1.55, 3.03	<0.001

740 Supplemental Table 2. Univariable and multivariable logistic regression model. *Chronic medication use
741 was defined within 1 year prior to baseline; corticosteroid use was defined within 30 days of baseline. In
742 all cases the population median was imputed for missing variables (Body mass index was missing for 479
743 participants, serum albumin was missing for 72 participants, hemoglobin was missing for 46 participants).
744 Abbreviations eGFR_{CRE-CYS} = estimated Glomerular Filtration Rate calculated using the 2021 race-free
745 combined serum creatinine and cystatin C equation, ACEi/ARB = Angiotensin Converting Enzyme
746 Inhibitor/Angiotensin Receptor Blocker.
747

748 **Supplemental Table 3. Characteristics of patients with severe eGFR discrepancy**

	Overall	Severe eGFR discrepancy
Covariates	N=1988	N=139
Age	66 (14)	68 (13)
Female Sex	965 (48.5)	60 (43.2)
Race/Ethnicity		
White	1555 (78.2)	114 (82.0)
Black	184 (9.3)	10 (7.2)
Hispanic	89 (4.5)	6 (4.3)
Asian	72 (3.6)	4 (2.9)
Other	88 (4.4)	5 (3.6)
Body Mass Index (kg/m²)		
Underweight (<18.5)	54 (3.6)	4 (4.6)
Normal (18.5 - 24.9)	442 (29.4)	28 (32.2)
Overweight (25 - 29.9)	515 (34.2)	26 (29.9)
Obese (≥30)	493 (32.8)	29 (33.3)
Comorbidities		
Hypertension	1600 (80.5)	124 (89.2)
Coronary Artery Disease	987 (49.6)	99 (71.2)
Diabetes Mellitus	1008 (50.7)	112 (80.6)
Cirrhosis	105 (5.3)	20 (14.4)
Human Immunodeficiency Virus	82 (4.1)	6 (4.3)
Smoking	806 (40.5)	67 (48.2)
Malnutrition	275 (13.8)	21 (15.1)
Medication Use		
ACEi/ARB	1128 (56.7)	77 (55.4)
Proton Pump Inhibitors	1291 (64.9)	115 (82.7)
Diuretics	1282 (64.5)	122 (87.8)
Labs		
Serum Creatinine (mg/dL)	1.62 (1.03)	1.56 (0.65)
Serum Albumin (g/dL)		
<3.0	297 (15.5)	77 (55.4)
3.0-3.49	187 (9.8)	27 (19.4)
3.5-3.9	280 (14.6)	20 (14.4)
≥4.0	1152 (60.1)	15 (10.8)
Blood Urea Nitrogen (mg/dL)		
≤17	501 (25.2)	4 (2.9)
17-25	526 (26.5)	6 (4.3)
25-39	482 (24.3)	30 (21.6)
>39	478 (24.1)	99 (71.2)
Hemoglobin (g/dL)		
≤10.0	597 (30.0)	111 (79.9)
10.0-11.9	505 (25.4)	18 (12.9)
≥12.0	886 (44.6)	10 (7.2)
Cancer types		
Urothelial	92 (4.6)	5 (3.6)
Brain	40 (2.0)	2 (1.4)
Breast	228 (11.5)	4 (2.9)
Gastrointestinal	177 (8.9)	11 (7.9)
Gynecologic	141 (7.1)	5 (3.6)
Head & Neck	50 (2.5)	5 (3.6)
Leukemia	129 (6.5)	21 (15.1)

Lymphoma	123 (6.2)	19 (13.7)
Melanoma	29 (1.5)	3 (2.2)
Prostate	147 (7.4)	5 (3.6)
Kidney	162 (8.1)	5 (3.6)
Sarcoma	4 (0.2)	0 (0.0)
Testicular	1 (0.1)	0 (0.0)
Thoracic	114 (5.7)	17 (12.2)
Thyroid	43 (2.2)	4 (2.9)
Skin (Other)	298 (15.0)	13 (9.4)

749
750 **Supplemental Table 3.** Severe eGFR discrepancy was defined as eGFR_{CYS} more than 50% lower than
751 eGFR_{CRE} and eGFR_{CYS} < 30mL/min/1.73m². Count and percent or mean and standard deviations are
752 shown. Body mass index was missing for 479 participants, serum albumin was missing for 72
753 participants, hemoglobin was missing for 46 participants. The remaining data was complete. The cohort
754 median was imputed for missing data. Cancer type was determined by the most common cancer-related
755 diagnosis code appearing prior to the baseline date. Abbreviations: eGFR = estimated glomerular filtration
756 rate, ACEi/ARB = Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker.
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791

792

Supplemental Table 4. Predictors of severe eGFR discrepancy

Covariates	Severe discrepancy group (N=139) Vs. Reference group (N= 1409)					
	Univariable			Multivariable		
	OR	95% CI	p-value	Adj OR	95% CI	p-value
Age (per 10 years)	1.16	1.02, 1.32	0.031	1.03	0.86, 1.25	0.743
Male Sex	0.83	0.58, 1.18	0.308	0.81	0.51, 1.29	0.38
White Race	1.35	0.87, 2.15	0.197	1.84	1.06, 3.29	0.033
Body mass index						
Normal weight	REF	—		—	—	
Underweight	1.52	0.43, 4.20	0.463	1.18	0.26, 4.43	0.82
Overweight	1.19	0.77, 1.89	0.446	2.22	1.26, 4.01	0.007
Obese	0.91	0.53, 1.57	0.743	1.98	0.99, 4.00	0.053
Smoking	1.50	1.05, 2.12	0.024	0.77	0.48, 1.21	0.26
Comorbidities						
Hypertension	2.39	1.42, 4.31	0.002	0.62	0.28, 1.40	0.24
Coronary Artery Disease	3.24	2.23, 4.80	<0.001	1.14	0.66, 1.98	0.64
Diabetes Mellitus	5.36	3.53, 8.42	<0.001	1.71	0.98, 3.02	0.061
Cirrhosis	5.21	2.92, 9.02	<0.001	2.80	1.31, 5.98	0.008
Human Immunodeficiency Virus	0.98	0.37, 2.13	0.963			
Malnutrition	1.23	0.74, 1.97	0.406			
Thyroid disease	1.70	1.16, 2.45	0.005	1.17	0.90, 1.51	0.245
Medication Use*						
ACEi/ARB	0.99	0.70, 1.41	0.968			
Proton Pump Inhibitors	3.15	2.04, 5.07	<0.001	1.06	0.58, 1.98	0.85
Diuretics	5.34	3.27, 9.28	<0.001	1.71	0.87, 3.50	0.13
Corticosteroid use	6.67	4.62, 9.64	<0.001	2.38	1.49, 3.80	<0.001
Baseline Labs						
eGFR _{CRE-CYS}	0.95	0.94, 0.96	<0.001	0.98	0.97, 0.99	<0.001
Albumin (g/dL)						
≥4.0	REF	—		—	—	
3.0-3.9	12.7	7.13, 23.7	<0.001	3.91	2.00, 7.96	<0.001
<3.0	54.4	31.0, 102	<0.001	12.3	6.14, 26.0	<0.001
Hemoglobin (g/dL)						
≥12.0	REF	—		—	—	
10.0-11.9	3.77	1.76, 8.57	<0.001	1.50	0.64, 3.78	0.36
≤10.0	31.3	17.0, 64.6	<0.001	3.59	1.64, 8.44	<0.001

793
794
795
796
797
798
799
800

Supplemental Table 4. Univariable and multivariable logistic regression model for severe group defined as eGFR_{CYS} more than 50% lower than eGFR_{CRE} and eGFR_{CYS} <30 ml/min/1.73m². *Chronic medication use was defined within 1 year prior to baseline; corticosteroid use was defined within 30 days of baseline. Abbreviations: eGFR_{CRE-CYS} = estimated Glomerular Filtration Rate calculated using the 2021 race-free combined serum creatinine and cystatin C equation, ACEi/ARB = Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker.

802 **Supplemental Table 5. Predictors of Vancomycin level > 30µg/dL**

Covariates	Predictors of Vancomycin level > 30µg/dL(N=55) Vs. <30µg/dL (N=227)					
	Univariable			Multivariable		
	OR	95% CI	p-value	Adj OR	95% CI	p-value
Age (per 10 years)	0.79	0.65, 0.97	0.023	0.73	0.57, 0.93	0.010
Male Sex	1.32	0.73, 2.38	0.36	1.47	0.64, 3.73	0.39
White Race	1.54	0.71, 3.72	0.30	1.38	0.61, 3.48	0.460
eGFR discrepancy	2.89	1.40, 6.58	0.006	2.30	1.05, 5.51	0.047
Body mass index	1.04	0.99, 1.09	0.096	1.04	0.98, 1.09	0.18
Smoking	0.91	0.50, 1.64	0.75			
Comorbidities						
Hypertension	1.41	0.60, 3.90	0.47			
Coronary Artery Disease	1.27	0.67, 2.56	0.48			
Diabetes Mellitus	3.28	1.36, 9.77	0.016	2.38	0.91, 7.47	0.098
Cirrhosis	0.94	0.36, 2.16	0.89			
Malnutrition	0.49	0.14, 1.30	0.19			
Thyroid disease	0.86	0.44, 1.63	0.66			
Medication Use*						
ACEi/ARB	0.96	0.53, 1.74	0.90			
Proton Pump Inhibitors	1.27	0.53, 3.51	0.62			
Diuretics	1.76	0.76, 4.83	0.22			
Corticosteroids	3.51	1.86, 7.03	<0.001	2.91	1.47, 6.02	0.0030
Baseline Labs						
eGFR _{CRE-CYS}	0.99	0.98, 1.00	0.043	0.99	0.97, 1.00	0.032
Albumin (g/dL)						
≥4.0	-	-	-			
3.0 to <4.0	2.73	0.72, 17.9	0.20			
<3.0	3.05	0.85, 19.6	0.14			
Hemoglobin (g/dL)						
≥12.0	-	-	-			
10.0 to <12.0	2.57	0.40, 50.4	0.40			
≤10.0	5.05	1.00, 92.1	0.12			

803
804 Supplemental Table 5. Univariable and multivariable logistic regression model predicting Vancomycin
805 trough level > 30 µg/dL. eGFR discrepancy defined as eGFR_{CYS} > 30% lower than eGFR_{CRE}.
806 Abbreviations: eGFR_{CRE-CYS} = estimated Glomerular Filtration Rate calculated using the 2021 race-free
807 combined serum creatinine and cystatin C equation, ACEi/ARB = Angiotensin Converting Enzyme
808 Inhibitor/Angiotensin Receptor Blocker.
809

810 **Supplemental Table 6. Deidentified case summaries of clinical digoxin toxicity**

811

65-70-year-old woman with atrial fibrillation and congestive heart failure	Admitted for hypercalcemia due to refractory multiple myeloma. She developed bradycardia with AV block, altered mental status, and hyperkalemia while on digoxin 0.25 mg daily, and her digoxin trough level was 3.8 ng/mL. She was treated with digoxin immune fab followed by improvement in bradycardia and mental status. Digoxin was permanently discontinued.
60-65-year-old woman with metastatic neuroendocrine cancer and carcinoid heart disease	Admitted for pulmonic and tricuspid valve replacement surgery and developed recurrent atrial flutter during a prolonged hospital stay. She was treated with digoxin load (0.25mg intravenous for 3 doses) followed by maintenance digoxin 0.125mg oral daily. On hospital day 83, she developed nausea and vomiting attributed to elevated digoxin (trough level was 2.1 ng/mL) and her symptoms fully resolved with discontinuation of digoxin.

812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841

842 **Supplemental Table 7. Predictors of 30-day mortality**

Covariates	30-day mortality					
	Univariable			Multivariable		
	HR	95% CI	p-value	Adj HR	95% CI	p-value
Age (per 10 years)	1.01	0.89, 1.14	0.93	1.04	0.90, 1.18	0.614
Male Sex	0.80	0.56, 1.13	0.20	1.22	0.85, 1.75	0.28
White Race	1.60	0.99, 2.57	0.054	1.71	1.04, 2.79	0.034
Body mass index						
Normal (18.5 - 24.9)	REF	—		—	—	
Under weight (<18.5)	1.20	0.47, 3.07	0.70	0.97	0.37, 2.53	0.96
Overweight (25 - 29.9)	0.96	0.64, 1.44	0.84	1.06	0.69, 1.62	0.80
Obese (≥ 30)	0.57	0.33, 0.98	0.041	1.15	0.66, 2.00	0.62
eGFR discrepancy	7.57	5.12, 11.2	<0.001	1.97	1.29, 3.01	0.002
Smoking	1.22	0.86, 1.71	0.26			
Comorbidities						
Hypertension	0.86	0.57, 1.31	0.49			
Coronary Artery Disease	2.10	1.46, 3.03	<0.001	0.99	0.66, 1.51	0.98
Diabetes Mellitus	2.46	1.68, 3.60	<0.001	1.03	0.67, 1.59	0.89
Cirrhosis	2.70	1.62, 4.49	<0.001	1.11	0.64, 1.93	0.70
Human Immunodeficiency Virus	1.11	0.49, 2.53	0.80			
Malnutrition	0.61	0.34, 1.11	0.11			
Thyroid disease	1.27	0.87, 1.83	0.21			
Medication Use*						
ACEi/ARB	0.71	0.50, 1.00	0.049	0.90	0.60, 1.34	0.59
Proton Pump Inhibitors	2.18	1.42, 3.35	<0.001	1.20	0.74, 1.94	0.47
Diuretics	2.00	1.32, 3.04	0.001	0.67	0.40, 1.11	0.12
Corticosteroids	5.02	3.56, 7.07	<0.001	1.58	1.09, 2.30	0.017
Baseline Labs						
eGFR _{CRE-CYS}	0.98	0.97, 0.99	<0.001	0.99	0.98, 1.00	0.027
Albumin (g/dL)						
≥4.0	REF	—		—	—	
3.0 to <4.0	16.3	6.32, 42.0	<0.001	7.17	2.62, 19.6	<0.001
<3.0	96.3	39.2, 237	<0.001	31.8	11.8, 86.2	<0.001
Hemoglobin (g/dL)						
≥12.0	REF	—		—	—	
10.0 to <12.0	6.10	2.45, 15.2	<0.001	2.00	0.77, 5.22	0.15
≤10.0	28.8	12.6, 65.5	<0.001	2.93	1.18, 7.25	0.020

843
844 Supplemental Table 7. Univariable and multivariable Cox model for 30-day mortality. eGFR discrepancy
845 defined as eGFR_{CYS} > 30% lower than eGFR_{CRE}. *Chronic medication use was defined within 1 year prior
846 to baseline; corticosteroid use was defined within 30 days of baseline. In all cases the population median
847 was imputed for missing variables (body mass index was missing for 479 participants, serum albumin was
848 missing for 72 participants, hemoglobin was missing for 46 participants). Abbreviations: eGFR_{CRE-CYS} =
849 estimated Glomerular Filtration Rate calculated using the 2021 race-free combined serum creatinine and
850 cystatin C equation, ACEi/ARB = Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker.
851